OliX Pharmaceuticals,Inc
KOE: 226950.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dong-Ki Lee
- Employees
- 72
- Headquarters
- Suwon-si, South Korea
- IPO year
- 2018
- Market cap
- ₩3.4T
- Website
- http://www.olixpharma.com
Loading 226950…
Loading profile data…Frequently asked questions about 226950
What does OliX Pharmaceuticals,Inc (226950.KQ) do?
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkl...
Where does 226950.KQ trade?
OliX Pharmaceuticals,Inc (226950.KQ) trades on the KOSDAQ.
What sector is 226950.KQ in?
OliX Pharmaceuticals,Inc (226950.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OliX Pharmaceuticals,Inc?
Dong-Ki Lee is the chief executive officer of OliX Pharmaceuticals,Inc (226950.KQ).
Where is OliX Pharmaceuticals,Inc headquartered?
OliX Pharmaceuticals,Inc is headquartered in South Korea.
Does 226950.KQ pay a dividend?
OliX Pharmaceuticals,Inc (226950.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 226950.KQ go public?
OliX Pharmaceuticals,Inc (226950.KQ) completed its initial public offering in 2018.